A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3 RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL, MULTICENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF MK-2870 MONOTHERAPY VERSUS TREATMENT OF PHYSICIAN¿S CHOICE AS SECOND-LINE TREATMENT FOR PARTICIPANTS WITH RECURRENT OR METASTATIC CERVICAL CANCER (TROFUSE-020/GOG- 3101/ENGOT-CX20)

Intervention/treatment:
MK-2870 (SKB264)
Medical condition:
CERVICAL CANCER
Protocol code:
MK-2870-020
Control number:
286949
Status:
Active, not recruiting
Approved:
June 13, 2024
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06459180
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: FEMALE
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Toll Free Number
Role
CONTACT
Phone:
1-888-577-8839
Sponsor
MERCK CANADA INC

Locations

British Columbia

BC Cancer Kelowna ( Site 4007)
Kelowna, British Columbia, V1Y 5L3
RECRUITING
Name
Study Coordinator
Role
CONTACT
Phone:
+1 250-712-3996
BC Cancer Surrey ( Site 4006)
Surrey, British Columbia, V3V 1Z2
RECRUITING
Name
Study Coordinator
Role
CONTACT
Phone:
604-930-2098
BC Cancer Victoria ( Site 4008)
Victoria, British Columbia, V8R 6V5
RECRUITING
Name
Study Coordinator
Role
CONTACT
Phone:
250-519-5500

Ontario

Hamilton Health Sciences-Juravinski Cancer Centre ( Site 4003)
Hamilton, Ontario, L8V 5C2
RECRUITING
Name
Study Coordinator
Role
CONTACT
Phone:
905-387-9495 x 64417
Royal Victoria Regional Health Centre ( Site 4009)
Barrie, Ontario, L4M 6M2
RECRUITING
Name
Study Coordinator
Role
CONTACT
Phone:
705 728-9090x66228

Quebec

Centre Hospitalier de l'Université de Montréal ( Site 4001)
Montreal, Quebec, H2X 0C1
RECRUITING
Name
Study Coordinator
Role
CONTACT
Phone:
514-890-8000 x 30777
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 4002)
Québec, Quebec, G1J 1Z4
RECRUITING
Name
Study Coordinator
Role
CONTACT
Phone:
418-525-4444 p 67322
McGill University Health Centre ( Site 4000)
Montreal, Quebec, H4A 3J1
RECRUITING
Name
Study Coordinator
Role
CONTACT
Phone:
514 934 1934 x31975
Did you find what you were looking for?

Contacts and resources